Romanian drug manufacturer Antibiotice Iasi reported a net profit of RON 74.194 million in H1 2024, 19.66 percent up year-over-year, according to a report sent on Wednesday to the Bucharest Stock Exchange.
The company’s net turnover (revenues from contracts with clients) as of end-June 2024 amounted to RON 350.85 million (plus 11.07 percent), of which the Romanian market accounted for RON 201.84 million (up 2.94 percent year-over-year), and the international market for RON 149.01 million (up 25 percent).
As of this year, Antibiotice started sales of injectable products in Italy, Poland, France, Bulgaria. Also, the first delivery to the United Arab Emirates was made this June.
Antibiotice Iasi is listed in the Premium category of the Bucharest Stock Exchange since 1997. The company’s majority shareholder is the Health Ministry with 53.02 percent of the subscribed and paid-up capital.
The company’s basic activity consists of the production of oral anti-infectives, being the only Romanian pharmaceutical company that delivers sterile anti-infective powders for injectable treatments. The Iasi-based drug manufacturer is the leader in the production intended for Romanian hospitals, holding the highest domestic market share for topical products (ointments, creams, gels). Also, it controls a major segment of the market for cardiovascular, central nervous system and anti-cancer agents.
AGERPRES
